Next Generation Sequencing Market, 2022 Dublin, March

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
34
Next Generation Sequencing Market, 2022

Dublin, March 27, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Next Generation Sequencing Global market - Forecast to 2022" report to their offering. The global Next Generation Sequencing market is expected to grow at a double digit CAGR to reach $14,722.5 million by 2022.

The time and cost to sequence has tremendously reduced since the first human genome was sequenced, which took a decade time and around $3 billion. But now a human genome can be sequenced at a cost of just $1,000 in one to two days. In the last five years, the sequencing cost has rapidly reduced and this is supposed to have a huge impact on the NGS market in the coming years. The NGS market is classified based on products, technology, end users, application and geography. The global NGS products are further divided into instruments, services and workflow products. The NGS technology is segmented into reversible terminator sequencing, ion semiconductor sequencing, sequencing by ligation, single molecule real time sequencing (SMRT), and others. The NGS application market is segmented in two different ways, one by sequencing process and the other by field of application. The NGS application market by type of sequencing process has been categorized into genomics, epigenomics, transriptomics, and others. By field of application, the market has been divided into diagnostics, drug discovery and development, biomarker discovery, agriculture and animal research, and others. The NGS market by end users is divided into academic research laboratories, hospitals and clinics, biotech and pharmaceuticals, and other end users, which include nonprofit organizations and commercial labs. Further, the NGS market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World. Key Topics Covered: 1. Executive Summary 2. Introduction 2.1 Key Take Aways 2.2 Report Description 2.3 Markets Covered 2.4 Stakeholders 2.5 Research Methodology 2.5.1 Market Size Estimation 2.5.2 Market Crackdown and Data Triangulation 2.5.3 Secondary Sources 2.5.4 Primary Sources 2.5.5 Key Data Points from Secondary Sources 2.5.6 Key Data Points from Primary Sources 2.5.7 Assumptions 3. Market Analysis 3.1 Introduction 3.2 Market Segmentation 3.3 Factors Influencing Market 3.3.1 Drivers and Opportunities 3.3.1.1 Reduced Cost and High Speed 3.3.1.2 Increased Usage In Clinical Diagnosis 3.3.1.3 Switch to NGS from Microarray Technology 3.3.1.4 New & Emerging Applications of NGS Technology 3.3.1.5 Growth of Personalized Medicine 3.3.1.6 Increased Medical Spending 3.3.2 Restraints and Threats 3.3.2.1 Complications In NGS Data Storage 3.3.2.2 Standardization of NGS For Diagnostic Application 3.3.2.3 Grants and Funding For NGS Infrastructure 3.3.2.4 Lack of Skilled Labor 3.3.2.5 Huge and Complex NGS Data Interpretation 3.3.2.6 Ethical and Legal Issues to NGS 3.4 Technological Advancements 3.4.1 Nanopore Sequencing Based Techniques 3.4.1.1 Electronic Biosciences Nanopore Sequencing 3.4.1.2 Roche's Nanotag Chemistry 3.4.1.3 Nabsys Nanopore Sequencer 3.4.1.4 Stratos Nanopore Sequencing 3.4.2 Electronic Optica'S Mad-Leem 3.4.3 Genapsys Genius 3.4.4 Lasergen'S Lightening Terminator Chemistry 3.4.5 Quantumdx Handheld Sequencing Instrument 3.4.6 Zs Genetics Adf-Stem 3.5 Regulatory Affairs 3.6 Porter'S Five Force Analysis 3.7 Patent Trends 3.8 Market Share Analysis by Major Players 4. Next Generation Sequencing Global Market, by Technology 4.1 Introduction 4.2 Reversible Terminator Sequencing 4.3 Ion Semicoductor Sequencing 4.4 Sequencing by Ligation 4.5 Single Molecule Real-Time Sequencing (SMRT) 4.6 Others 5. NGS Global Market, by Product Type 5.1 Introduction 5.1.1 Instruments 5.1.2 Services 5.1.2.1 Data Analysis Services 5.1.2.2 Sequencing Services 5.1.3 Workflow Products 6. Next-Generation Sequencing Global Market, by Application 6.1 Introduction 6.2 NGS Global Application Market, by Process 6.2.1 Genomics 6.2.1.1 Whole Genome Sequencing 6.2.1.2 Exome Sequencing 6.2.1.3 Target Resequencing 6.2.1.4 De Novo Sequencing 6.2.2 Epigenomics 6.2.2.1 Chip Sequencing 6.2.2.2 Methyl Sequencing 6.2.3 Transcriptomics 6.2.3.1 Rna Sequencing 6.2.4 Others 6.3 NGS Global Application Market, by Field Type 6.3.1 Diagnostics 6.3.1.1 Cancer Diagnostics 6.3.1.2 Infectious Disease Diagnostics 6.3.1.3 Genetic Screening 6.3.1.4 Transplantation Diagnostics 6.3.2 Drug Discovery and Development 6.3.3 Biomarker Discovery 6.3.4 Agriculture and Animal Research 6.3.5 Other Applications 7. Next-Generation Sequencing Global Market, by End Users 7.1 Introduction 7.2 Academic Research 7.3 Hospitals and Clinics 7.4 Biotech/Pharmaceuticals 7.5 Other End Users 8. Next-Generation Sequencing Global Market, by Region 9. Company Developments 9.1 Introduction 9.1.1 New Product Launch As A Major Growth Strategy of NGS Market Players 9.2 New Product Launch 9.3 Agreements, Partnerships & Collaborations 9.4 Acquisitions 9.5 Other Developments 10. Major Player Profiles 10.1 Agilent Technologies, Inc. 10.2 BGI (Beijing Genomics Institute) 10.3 Dnastar, Inc. 10.4 Eurofin Genomics 10.5 Illumina, Inc. 10.6 Oxford Nanopore Technologies Ltd 10.7 Pacific Biosciences of California, Inc. 10.8 Qiagen N.V. 10.9 Roche HoldiNGS Ag 10.10 Thermo Fisher Scientific, Inc. Companies Mentioned - 10X Genomics - Adaptive Biotechnologies Corporation - Agilent Technologies - Amoy Diagnostics CO - Archerdx - Asuragen - BGI - Biomatters LTD - Biomerieux - Cancer Genetics, INC. - Caredx, INC. - Danaher Corporation - Direct Genomics - DNA Electronics - Dnastar, INC. - Dnavision Sa - Electron Optica - Electronic Biosciences - Eurofins Scientific - Flowjo Llc - Genapsys,INC. - Genewiz - Genomatix Software Gmbh - Igenomix - Illumina, INC. - Invicta - Macrogen - Nabsys - Noblegen - Novogene - Oxford Nanopore Technologies - Pacific Biosciences - Qiagen N.V. - Quantumdx - Real Time Genomics - Roche Holdings - Seqomics - Seracare Life Sciences - Strand Lifesciences Pvt LTD - Stratos Genomics - Thermo Fisher Scientific, INC. - Toma Biosciences - Two Pore Guys, INC. - Vela Diagnostics - Veritas Genetics - Wafergen Biosystems - ZS Genetics For more information about this report visit http://www.researchandmarkets.com/research/3c...generation

About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Molecular Diagnostics

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PMET's High-Stakes Call on Shaakichiuwaanaan Update

Updated Category News Views 51

Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...

Continue Reading
Elong Kicks Off Central Asia Strategy with Almaty Launch

Updated Category News Views 70

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 68

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
myKaarma's Off-Site Wash: A Game Changer for Dealers

Updated Category News Views 37

myKaarma Offers Time and Convenience Boost with Wash Option When was the last time a car dealership didn't have folks lined up waiting for a wash? Dragging out your car's service longer than a Sunday sermon. But today, myKaarma, the folks behind dealership customer interaction magic, cracked open another bottle of convenience with their latest offering: off-site,...

Continue Reading
Lyons Steers Home Services Brands to New Franchise Heights

Updated Category News Views 87

Big Changes Ahead for Home Franchise Concepts It's a fresh dawn over at Home Franchise Concepts, and Cory Lyons has been tapped to lead four pivotal brands as their new Brand President. Now, if you're looking at this lineup—Kitchen Tune-Up, Bath Tune-Up, The Tailored Closet, and PremierGarage—you know there's more than just nails and hammers involved. Lyons isn't just...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 105

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Updated Category News Views 23

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Continue Reading
Mass-Vac Unleashes Advanced Vacuum Protection

Updated Category News Views 92

Introducing a Heavy-Duty Defender for Lab Systems When it comes to safeguarding central laboratory vacuum systems, you can bet there’s more at play than meets the eye. Mass-Vac, Inc., steps up and doesn't mess around with their latest innovation—the MV Multi-Trap® Vacuum Inlet Trap. Climbing aboard in November 2026, this stout guardian against contamination is out to...

Continue Reading
Retail's AI Ambitions Clash with In-Store Data Realities

Updated Category News Views 127

AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...

Continue Reading
Gen Z, Millennials Lean on AI Amid Fiscal Crunch

Updated Category News Views 78

AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...

Continue Reading
ws Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles